Illumina to Record $1.47 Goodwill Impairment Charge in Q2 After Grail Spin-Off
Illumina (ILMN) said Thursday it estimates a goodwill impairment charge of $1.47 billion in Q2, in relation to the recent spin-off of cancer diagnostic test maker Grail (GRAL). Illumina also expects a
Barclays Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $100
Barclays analyst Luke Sergott maintains $Illumina(ILMN.US)$ with a sell rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 39.9% and a total a
Express News | Illumina Inc - Charge as a Result of Impairment Test Performed by Co for Goodwill and Non-Amortizing in-Process Research and Development
Express News | Illumina Inc - Estimates That It Will Recognize an Impairment Charge for Grail Ipr&D Intangible Asset in Q2 of 2024 Equal to $420 Mln
Express News | Illumina Inc - Does Not Expect Any Material Future Cash Expenditures Related to Impairments
Express News | Illumina Inc - Estimates That It Will Recognize a Goodwill Impairment Charge in the Second Quarter of 2024 Equal to $1,466 Million
Baird Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $119
Baird analyst Catherine Ramsey Schulte maintains $Illumina(ILMN.US)$ with a hold rating, and adjusts the target price from $128 to $119.According to TipRanks data, the analyst has a success rate of 52
Cancer detection product supplier Grail (GRAL.US) will debut on Nasdaq tonight, having split from Illumina (ILMN.US).
Grail, a cancer detection product supplier split off from life science company Illumina, went public on Nasdaq on Tuesday.
Grail to Begin Trading as Illumina Completes Spinoff
Cancer blood test developer Grail launches trading on Nasdaq, valuing it at about $7 billion
Nearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it would spin off the cancer blood test developer. In July 2021, Illumina said it
Illumina Completes Grail Spin-Off Into Publicly Traded Entity, Holds Minority Stake
Illumina (ILMN) late Monday said it has successfully spun off its former Grail cancer diagnostics unit into a stand-alone public company that will trade under the ticker GRAL starting Tuesday. As part
Illumina Finishes Spinning Off Cancer-Test Maker Grail -- WSJ
By Peter Loftus Grail is back to being an independent company after a tumultuous few years, and its CEO says its making progress toward broader use of its cancer-detection blood test. Illumina, the
GRAIL Will Be Listed And Commence Regular-Way Trading On The Nasdaq Under The Symbol "GRAL" As Of June 25, 2024.
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25GRAIL is Building and Scaling a Groundbreaking New Cancer Screening TechnologyGRAIL, Inc. (NASDAQ:GRAL, formerly GRAIL, LLC
Express News | Illumina Inc - Grail Spin-off Complete; Grail to Begin Regular Way Trading as "Gral" on June 25
Express News | Illumina Completes the Divestiture of Grail
GRAIL to Begin Trading on the Nasdaq Stock Exchange
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25 GRAIL is Building and Scaling a Groundbreaking New Cancer Screening Technology GRAIL, Inc. (NASDAQ:GRAL, formerly GRAIL, LLC)), a
Illumina Completes the Divestiture of GRAIL
Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. GRAIL will begin regular way trading on Nasdaq on Tuesday, June 25 under the ticker symbol "GRAL." Illumina will continue to trade on Nasdaq under the ticker symbol "ILMN."
Long-term Beneficiaries of AI, According to Goldman Sachs
Guggenheim Initiates Illumina(ILMN.US) With Buy Rating, Announces Target Price $138
Guggenheim analyst Subbu Nambi initiates coverage on $Illumina(ILMN.US)$ with a buy rating, and sets the target price at $138.According to TipRanks data, the analyst has a success rate of 50.0% and a
Express News | Illumina Inc : Guggenheim Cuts Target Price to $138 From $159